SB 569 expands the prescribing authority of certain Advanced Practice Registered Nurses (APRNs) in Oklahoma. Under the bill, Certified Nurse Practitioners, Clinical Nurse Specialists, and Certified Nurse-Midwives who have completed at least three years of physician-supervised practice with prescriptive authority may apply to the Oklahoma Board of Nursing for independent prescriptive authority. The Board would review applications, approve or deny them, allow reapplication, set fees, and retain the power to suspend or revoke authority for good cause. The authority would last through the current license period and be renewed with the APRN license.
The bill also adds malpractice insurance requirements for APRNs, generally requiring at least $1 million per occurrence and $3 million aggregate coverage, with a federal-employment exception. It directs the Board of Nursing to adopt advertising rules for APRNs and clarifies that the bill does not expand APRNs’ authority beyond what state law otherwise permits. In addition, it requires the medical licensing boards to post and maintain online lists of physicians available to supervise APRNs, and it creates or updates several statutory definitions and cross-references in the Nursing Practice Act, Pharmacy Act, and Controlled Dangerous Substances Act to reflect the new independent prescriptive authority framework.
In the controlled substances provisions, the bill distinguishes between APRNs who still practice under physician supervision and those who obtain independent prescriptive authority. Both groups of eligible APRNs may prescribe Schedule III, IV, and V controlled dangerous substances if they meet registration and practice requirements, while certified registered nurse anesthetists retain their separate authority to order, select, obtain, and administer certain controlled substances in anesthesia-related settings. The bill also updates pharmacy-law definitions so APRNs with prescribing authority are treated as licensed practitioners for those purposes.
The general sentiment reflected by the bill text is supportive of expanding APRN practice authority while preserving regulatory oversight. The measure appears designed to increase access to care by allowing experienced APRNs to prescribe independently after a defined supervised practice period, but it also keeps safeguards in place through Board review, malpractice coverage, supervision rules for non-independent APRNs, and formulary limits. No committee transcript or vote record was provided, so there is no recorded floor or committee debate to indicate broader legislative sentiment beyond the bill’s structure and sponsorship.
The main points of potential contention are the shift away from physician supervision for some APRNs, the scope of independent prescribing authority, and the insurance and regulatory requirements tied to that authority. Physicians and medical boards may be concerned about patient safety, supervision standards, and the boundaries of APRN practice, while nursing advocates are likely to support the bill as a professional scope-of-practice expansion. The requirement that supervising physicians be listed online and the Board’s authority to set fees, revoke authority, and regulate advertising suggest the bill attempts to balance those competing interests.
SB 569 would amend multiple sections of Oklahoma law, primarily in Title 59 and Title 63, to create a new pathway for independent prescriptive authority for certain APRNs and to conform related pharmacy and controlled-substances statutes. It would change the Oklahoma Nursing Practice Act and Pharmacy Act definitions, authorize the Board of Nursing to grant and regulate independent prescriptive authority, require malpractice insurance, and direct rulemaking on advertising and supervision. It would also update controlled dangerous substances provisions so APRNs with and without independent authority are treated differently for prescribing Schedule III-V drugs, while preserving existing CRNA anesthesia-related authority. The bill would take effect November 1, 2025.
The bill’s overall tone is pro-expansion of APRN practice authority, with a strong emphasis on regulatory safeguards rather than deregulation. The text suggests support for allowing experienced APRNs to practice more independently, likely reflecting a policy goal of improving access to care and modernizing scope-of-practice rules. Because no committee transcripts or vote history were provided, there is no direct evidence of opposition or support from legislators in debate, but the bill’s detailed oversight provisions indicate an attempt to address anticipated concerns from the medical community.
The most notable contention is likely between nursing advocates, who would favor independent prescriptive authority for qualified APRNs, and physician or medical-board interests, which may prefer continued supervision. Specific flashpoints include the three-year supervised practice threshold, the ability of APRNs to prescribe controlled dangerous substances without physician supervision, the requirement for malpractice coverage, and the Board’s authority to suspend or revoke independent authority. The mandated public posting of supervising physicians and the formulary/advisory structure also suggest concern over maintaining physician oversight and limiting APRN prescribing to approved boundaries.